Author:
Zanti Maria,Loizidou Maria A.,O’Mahony Denise G.,Dorling Leila,Dennis Joe,Devilee Peter,Easton Douglas F.,Panayiotidis Mihalis I.,Hadjisavvas Andreas,Michailidou Kyriaki
Abstract
Introduction: It is estimated that around 5% of breast cancer cases carry pathogenic variants in established breast cancer susceptibility genes. However, the underlying prevalence and gene-specific population risk estimates in Cyprus are currently unknown.Methods: We performed sequencing on a population-based case-control study of 990 breast cancer cases and 1094 controls from Cyprus using the BRIDGES sequencing panel. Analyses were conducted separately for protein-truncating and rare missense variants.Results: Protein-truncating variants in established breast cancer susceptibility genes were detected in 3.54% of cases and 0.37% of controls. Protein-truncating variants in BRCA2 and ATM were associated with a high risk of breast cancer, whereas PTVs in BRCA1 and PALB2 were associated with a high risk of estrogen receptor (ER)-negative disease. Among participants with a family history of breast cancer, PTVs in ATM, BRCA2, BRCA1, PALB2 and RAD50 were associated with an increased risk of breast cancer. Furthermore, an additional 19.70% of cases and 17.18% of controls had at least one rare missense variant in established breast cancer susceptibility genes. For BRCA1 and PALB2, rare missense variants were associated with an increased risk of overall and triple-negative breast cancer, respectively. Rare missense variants in BRCA1, ATM, CHEK2 and PALB2 domains, were associated with increased risk of disease subtypes.Conclusion: This study provides population-based prevalence and gene-specific risk estimates for protein-truncating and rare missense variants. These results may have important clinical implications for women who undergo genetic testing and be pivotal for a substantial proportion of breast cancer patients in Cyprus.
Subject
Genetics (clinical),Genetics,Molecular Medicine
Reference26 articles.
1. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies;Antoniou;Am. J. Hum. Genet.,2003
2. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes;Buys;Cancer,2017
3. Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis;Cybulski;Lancet Oncol.,2015
4. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology;Daly;J. Natl. Compr. Canc Netw.,2021
5. Breast cancer risk genes - association analysis in more than 113,000 women;Dorling;N. Engl. J. Med.,2021